Cellosaurus H69AR (CVCL_3513)

Cell line name H69AR
Synonyms H-69AR
Accession CVCL_3513
Resource Identification Initiative To cite this cell line use: H69AR (RRID:CVCL_3513)
Comments Part of: MD Anderson Cell Lines Project.
Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
Omics: Protein expression by reverse-phase protein arrays.
Disease Small cell lung carcinoma (NCIt: C4917)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_1579 (NCI-H69)
Children: CVCL_4T78 (H69PR)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC

Markers:
AmelogeninX
CSF1PO10,12
D13S31712
D16S53911
D5S81811,13
D7S8209
TH018,9
TPOX10
vWA16,17
Web pages http://tcpaportal.org/mclp/
Publications

PubMed=2436751
Mirski S.E.L., Gerlach J.H., Cole S.P.C.
Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Cancer Res. 47:2594-2598(1987)

PubMed=1314068; DOI=10.1038/bjc.1992.103
Cole S.P.C., Pinkoski M.J., Bhardwaj G., Deeley R.G.
Elevated expression of annexin II (lipocortin II, p36) in a multidrug resistant small cell lung cancer cell line.
Br. J. Cancer 65:498-502(1992)

Patent=US5489519
Deeley R.G., Cole S.P.C.
Multidrug resistance protein.
Patent number US5489519, 06-Feb-1996

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-11351
Cell line databases/resources IGRhCellID; H69AR
Ontologies BTO; BTO:0005367
CLO; CLO_0003610
Gene expression databases GEO; GSM169453
GEO; GSM827497
GEO; GSM986176